Novogene Co., Ltd. Logo

Novogene Co., Ltd.

688315.SS

(1.2)
Stock Price

12,83 CNY

5.41% ROA

7.74% ROE

33.42x PER

Market Cap.

6.021.339.196,00 CNY

1.68% DER

0.32% Yield

8.75% NPM

Novogene Co., Ltd. Stock Analysis

Novogene Co., Ltd. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Novogene Co., Ltd. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (3%), which means it has a small amount of debt compared to the ownership it holds

2 ROE

ROE in an average range (9.4%) suggests satisfactory profitability and decent utilization of shareholders' equity.

3 ROA

The stock's ROA (6.38%) indicates that it's doing well in making money from the things it owns. This makes it a good option to invest and make consistent profits.

4 Buffet Intrinsic Value

The company's stock presents an enticing opportunity as it appears undervalued (438) by Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

5 PBV

The stock's elevated P/BV ratio (4.64x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

6 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

7 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

9 Graham Number

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

10 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

11 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

Novogene Co., Ltd. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Novogene Co., Ltd. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Hold

Novogene Co., Ltd. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Novogene Co., Ltd. Revenue
Year Revenue Growth
2015 309.827.209
2016 458.473.019 32.42%
2017 739.349.026 37.99%
2018 1.053.561.692 29.82%
2019 1.534.828.907 31.36%
2020 1.490.027.645 -3.01%
2021 1.866.396.324 20.17%
2022 1.925.634.138 3.08%
2023 1.996.613.627 3.55%
2023 2.002.271.300 0.28%
2024 2.108.977.440 5.06%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Novogene Co., Ltd. Research and Development Expenses
Year Research and Development Expenses Growth
2015 45.461.981
2016 30.534.532 -48.89%
2017 50.360.514 39.37%
2018 79.415.117 36.59%
2019 125.708.258 36.83%
2020 112.314.986 -11.92%
2021 145.286.035 22.69%
2022 125.565.550 -15.71%
2023 166.221.533 24.46%
2023 124.182.171 -33.85%
2024 96.580.752 -28.58%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Novogene Co., Ltd. General and Administrative Expenses
Year General and Administrative Expenses Growth
2015 36.351.032
2016 50.842.681 28.5%
2017 15.497.869 -228.06%
2018 23.136.417 33.02%
2019 35.860.574 35.48%
2020 24.606.609 -45.74%
2021 29.709.387 17.18%
2022 32.357.815 8.18%
2023 485.545.429 93.34%
2023 27.470.338 -1667.53%
2024 -106.275.480 125.85%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Novogene Co., Ltd. EBITDA
Year EBITDA Growth
2015 46.690.962
2016 75.819.686 38.42%
2017 142.533.363 46.81%
2018 200.994.686 29.09%
2019 222.134.505 9.52%
2020 164.218.202 -35.27%
2021 388.072.862 57.68%
2022 393.298.618 1.33%
2023 257.266.543 -52.88%
2023 383.822.853 32.97%
2024 364.031.520 -5.44%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Novogene Co., Ltd. Gross Profit
Year Gross Profit Growth
2015 162.293.660
2016 220.060.765 26.25%
2017 316.482.527 30.47%
2018 451.826.077 29.95%
2019 600.936.471 24.81%
2020 523.345.985 -14.83%
2021 800.466.200 34.62%
2022 852.678.001 6.12%
2023 909.542.680 6.25%
2023 855.717.426 -6.29%
2024 877.567.776 2.49%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Novogene Co., Ltd. Net Profit
Year Net Profit Growth
2015 24.788.689
2016 39.130.903 36.65%
2017 80.502.576 51.39%
2018 97.098.451 17.09%
2019 114.285.890 15.04%
2020 36.539.135 -212.78%
2021 225.199.470 83.77%
2022 177.230.334 -27.07%
2023 200.961.384 11.81%
2023 178.059.764 -12.86%
2024 202.446.064 12.05%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Novogene Co., Ltd. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2015 0
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 1 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Novogene Co., Ltd. Free Cashflow
Year Free Cashflow Growth
2015 96.706.878
2016 -32.374.985 398.71%
2017 -442.170.984 92.68%
2018 70.339.909 728.62%
2019 -87.206.102 180.66%
2020 249.997.180 134.88%
2021 181.474.503 -37.76%
2022 86.728.051 -109.25%
2023 1.256.519 -6802.25%
2023 217.498.340 99.42%
2024 -17.528.507 1340.83%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Novogene Co., Ltd. Operating Cashflow
Year Operating Cashflow Growth
2015 142.980.000
2016 95.437.700 -49.82%
2017 54.770.621 -74.25%
2018 151.431.096 63.83%
2019 85.358.372 -77.41%
2020 342.073.087 75.05%
2021 293.473.741 -16.56%
2022 303.949.324 3.45%
2023 41.668.602 -629.44%
2023 334.197.677 87.53%
2024 32.783.050 -919.42%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Novogene Co., Ltd. Capital Expenditure
Year Capital Expenditure Growth
2015 46.273.122
2016 127.812.685 63.8%
2017 496.941.605 74.28%
2018 81.091.187 -512.82%
2019 172.564.474 53.01%
2020 92.075.907 -87.42%
2021 111.999.238 17.79%
2022 217.221.273 48.44%
2023 40.412.083 -437.52%
2023 116.699.336 65.37%
2024 50.311.557 -131.95%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Novogene Co., Ltd. Equity
Year Equity Growth
2015 40.521.254
2016 793.471.003 94.89%
2017 864.648.983 8.23%
2018 972.139.724 11.06%
2019 1.086.990.876 10.57%
2020 1.120.876.516 3.02%
2021 1.797.499.013 37.64%
2022 1.975.704.645 9.02%
2023 2.099.554.328 5.9%
2023 2.473.836.958 15.13%
2024 2.400.966.058 -3.04%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Novogene Co., Ltd. Assets
Year Assets Growth
2015 480.084.113
2016 1.227.066.523 60.88%
2017 1.352.574.448 9.28%
2018 1.471.357.886 8.07%
2019 1.970.157.577 25.32%
2020 2.024.732.082 2.7%
2021 2.859.351.915 29.19%
2022 3.048.274.366 6.2%
2023 3.018.011.770 -1%
2023 3.594.420.954 16.04%
2024 3.387.809.821 -6.1%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Novogene Co., Ltd. Liabilities
Year Liabilities Growth
2015 439.562.859
2016 433.595.519 -1.38%
2017 487.925.464 11.13%
2018 499.218.161 2.26%
2019 883.166.701 43.47%
2020 903.855.566 2.29%
2021 1.061.852.902 14.88%
2022 1.072.569.721 1%
2023 918.457.442 -16.78%
2023 1.120.583.995 18.04%
2024 985.873.830 -13.66%

Novogene Co., Ltd. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
5.06
Net Income per Share
0.44
Price to Earning Ratio
33.42x
Price To Sales Ratio
2.91x
POCF Ratio
22.27
PFCF Ratio
60.21
Price to Book Ratio
2.54
EV to Sales
2.78
EV Over EBITDA
21.23
EV to Operating CashFlow
21.13
EV to FreeCashFlow
57.4
Earnings Yield
0.03
FreeCashFlow Yield
0.02
Market Cap
6,02 Bil.
Enterprise Value
5,74 Bil.
Graham Number
7.62
Graham NetNet
2.35

Income Statement Metrics

Net Income per Share
0.44
Income Quality
1.5
ROE
0.08
Return On Assets
0.05
Return On Capital Employed
0.08
Net Income per EBT
0.84
EBT Per Ebit
1.11
Ebit per Revenue
0.09
Effective Tax Rate
0.14

Margins

Sales, General, & Administrative to Revenue
0.01
Research & Developement to Revenue
0.06
Stock Based Compensation to Revenue
-0
Gross Profit Margin
0.42
Operating Profit Margin
0.09
Pretax Profit Margin
0.1
Net Profit Margin
0.09

Dividends

Dividend Yield
0
Dividend Yield %
0.32
Payout Ratio
0
Dividend Per Share
0.05

Operating Metrics

Operating Cashflow per Share
0.66
Free CashFlow per Share
0.24
Capex to Operating CashFlow
0.63
Capex to Revenue
0.08
Capex to Depreciation
3.21
Return on Invested Capital
0.07
Return on Tangible Assets
0.05
Days Sales Outstanding
136.1
Days Payables Outstanding
35.42
Days of Inventory on Hand
59.34
Receivables Turnover
2.68
Payables Turnover
10.3
Inventory Turnover
6.15
Capex per Share
0.42

Balance Sheet

Cash per Share
3,11
Book Value per Share
5,88
Tangible Book Value per Share
5.77
Shareholders Equity per Share
5.83
Interest Debt per Share
0.1
Debt to Equity
0.02
Debt to Assets
0.01
Net Debt to EBITDA
-1.04
Current Ratio
2.4
Tangible Asset Value
2,36 Bil.
Net Current Asset Value
1,32 Bil.
Invested Capital
2133247352
Working Capital
1,34 Bil.
Intangibles to Total Assets
0.01
Average Receivables
0,71 Bil.
Average Payables
0,13 Bil.
Average Inventory
185002461.5
Debt to Market Cap
0.01

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Novogene Co., Ltd. Dividends
Year Dividends Growth
2022 0
2023 0 0%
2024 0 0%

Novogene Co., Ltd. Profile

About Novogene Co., Ltd.

Novogene Co., Ltd. provides genomic services and solutions worldwide. The company offers genomic solutions, such as human genome sequencing, gene regulation, single cell sequencing, animal and plant solutions, and microbial genome sequencing; and cancer genomic profiling, whole exome sequencing, and FFPE RNA sequencing, as well as clinical-grade whole exome sequencing services. It also provides NovoFocus, a next-generation sequencing based companion diagnostic assay for PARP inhibitor therapies; and NovoNeoantigen, a bioinformatics pipeline for the identification of cancer neoantigens with whole exome sequencing and whole transcriptome sequencing data from paired tumor-normal samples. Novogene Co., Ltd. has a strategic partnership with Hummingbird Bioscience Pte. Ltd. to support the development of investigational drug candidate HMBD-001, an anti-HER3 antibody to be evaluated for treatment of various tumor types, including NRG1-fusion driven cancers. The company was founded in 2011 and is headquartered in Beijing, China.

CEO
Dr. Ruiqiang Li
Employee
2.144
Address
Building 301
Beijing,

Novogene Co., Ltd. Executives & BODs

Novogene Co., Ltd. Executives & BODs
# Name Age
1 Ms. Yanping Li
Deputy General Manager
70
2 Mr. Yang Yu
Deputy General Manager
70
3 Dr. Ruiqiang Li
Founder, Chairman of the Board & Chief Executive Officer
70

Novogene Co., Ltd. Competitors